Error message

  • User warning: The following module is missing from the file system: entity. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/bootstrap.inc).
  • User warning: The following module is missing from the file system: entity_token. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/bootstrap.inc).
  • User warning: The following module is missing from the file system: path_breadcrumbs. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/bootstrap.inc).
×

COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

July 14, 2020
Fred Hutch Team Establishes a New CLIA Lab for Running Targeted-MS assays, Including a Novel CLIA-Approved HER2 Test

A major goal for NCI’s Cancer Proteomic Tumor Analysis Consortium (CPTAC) is to translate proteomic technologies into clinical use to improve treatment and diagnosis of cancer. Dr. Amanda Paulovich and team from the Fred Hutchinson Cancer Research Center (members of the CPTAC Consortium) have...
July 9, 2020
Lung Adenocarcinoma (LUAD) Discoveries from two NCI Proteomics Consortia

Two new studies released July 9th, 2020 in Cell unravel the biology of lung adenocarcinoma (LUAD) using a suite of molecular techniques that, combined, provide a more complete picture of the disease than ever before.
July 1, 2020
OCCPR Webinar: MSFragger

Join Dr. Alexey Nesvizhskii, Professor of Pathology and Computational Medicine & Bioinformatics at University of Michigan, as he speaks on our next OCCPR Webinar about his ultrafast MSFragger software. The webinar will take place on Wednesday, July 15th at 1pm - registration is free, but required...
June 16, 2020
In Case You Missed It: CPTAC Investigator Spotlight on Karin Rodland

The Investigator Spotlight Series was the brain child of Dr. Dawn Hayward, an NCI Communications Fellow at OCCPR, to highlight our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientist Dr. Karin Rodland. Enjoy!
June 2, 2020
CPTAC At AACR Virtual Meeting II

We are so excited to be a part of the AACR Virtual Meeting II, June 22-24, 2020! Join us for our Clinical Proteomic Tumor Analysis Consortium (CPTAC) Educational Session: Resources and Data Dissemination Tuesday June 23rd, 3:00-5:00 p.m.
May 21, 2020
Proteomics 3 Ways – An Efficient Analysis of Global, Glyco-, and Phospho-Proteomics

In a new study published in Analytical Chemistry, we see another example of ingenuity by NCI’s Office of Cancer Clinical Proteomic Research (OCCPR) Clinical Proteomic Tumor Analysis Consortium (CPTAC) scientists. In an effort to optimize analytical output and conserve hard-to-obtain biospecimen...
May 15, 2020
Joint Proteomic and Genomic Data Release for Head and Neck Squamous Cell Carcinoma

108 cases of the NCI’s Clinical Proteomic Tumor Analysis Program (CPTAC) Head and Neck Squamous Cell Carcinoma Discovery Study have been proteomically and genomically profiled! Each case includes HPV-negative, treatment naive and normal adjacent tissue, and includes proteomic ad phosphoproteomic data...
May 5, 2020
50 New AML Pathology Slides on TCIA-CPTAC Pathology Portal

50 new pathology slides from 33 new Acute Myeloid Leukemia (AML) subjects are now available on the TCIA-CPTAC Pathology Portal. The April 2020 image release brings the total number of AML pathology slides to 120 from 88 subjects, with most of them also having both tumor blood and marrow imaging. 
April 29, 2020
OCCPR Webinar: LinkedOmics

Scientists from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) program developed a powerful tool to explore associations between multiple types of omics datasets. The LinkedOmics software collects genomic, transcriptomic and proteomic datasets from The Cancer Genome Atlas (TCGA) and CPTAC...
April 21, 2020
CPTAC Researchers Identify New Features of Ovarian High-Grade Serous Cancer Associated with Patient Survival Rates and Alternative Drug Therapies

In a study published on April 21, in Cell Reports Medicine, researchers with the National Cancer Institutes’ (NCI) Clinical Proteomics Tumor Analysis Consortium (CPTAC) take a comprehensive look at the root causes of ovarian high-grade serous carcinoma (HGSC). Through integrated proteomic and genomic...

Pages

more

View all News and Announcements